LifeEdit will leverage its genome editing platform, derived from AgBiomes's proprietary microbial Genesis discovery platform, to internally develop cell and gene therapies that strengthen the company's genome editing enzymes platform. Using the platform, the company will continue to develop its array of novel RNA-guided nucleases and base editors that are active in mammalian cells.

AgBiome will retain rights to gene editing in agriculture, animal health, and diagnostics.

LifeEdit will also provide gene editing expertise to strategic partners within ElevateBio's portfolio of companies.

The new LifeEdit Therapeutics executive team include the following:

• Mitchell Finer, PhD, CEO (also president of ElevateBio BaseCamp)
• Tedd Elich, PhD, chief scientific officer
• Kareem Reda, chief operating officer (also chief business officer of ElevateBio)
• Clare Murray, vice president, head of corporate development and strategy

Improving the safety of gene therapies 2 different ways
Two groups of researchers have developed unique approaches to overcome the limitations of delivery of gene editing therapeutics. In a pair of new papers,...

A 'Pac-Man' like CRISPR system could enable larger gene edits
A new CRISPR tool utilizes Cas3 to remove larger than normal stretches of DNA both quickly and accurately. The tool, described in an October 19 article...

ERS Genomics licenses gene editing tech to FASMAC
ERS Genomics, which has access to foundational CRISPR/Cas9 intellectual property co-owned by Emmanuelle Charpentier, has signed an agreement with FASMAC...

Synthego introduces new CRISPR light control tech
Synthego has designed a new foundational technology for standardized precision and control of CRISPR-based genome editing inside cells using light.

Science serves society, a crucial concept for gene therapy governance
With a focus on science and society, the American Society of Gene & Cell Therapy Policy Summit commenced on September 24. The ensuing discussion revealed...